Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NGLSVnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1nBdGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP MU\TRW5ITVJ?
CAL-51 cell M4rmSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI3KG6P NIPYVoZUSU6JRWK=
ABC-1 cell M{Wxc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PYS2lvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?= M3niXXNCVkeHUh?=
A2780 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojZTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVk1KG6P NFPZOGJUSU6JRWK=
ES1 cell M2HqPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nRNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? NUTDeWdIW0GQR1XS
HUTU-80 cell M2DGRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= NIHZb5lUSU6JRWK=
NCI-H292 cell M4XTWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETP[XRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> M{jGeXNCVkeHUh?=
NB69 cell NFGwbpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7mSXgxUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= M4rvXnNCVkeHUh?=
ES8 cell M3LzNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHvRb21KdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Ihdk1? M1fuWHNCVkeHUh?=
BCPAP cell M4\remdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnLO41nUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= NXzQb5dSW0GQR1XS
T-24 cell M4rtPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2rYNmlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? M4r1W3NCVkeHUh?=
EW-16 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnXjTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlEhdk1? NGPBU2ZUSU6JRWK=
OVCAR-5 cell NYDCeVloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P MWXTRW5ITVJ?
SF126 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2ThXmlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2KG6P NYLBV5dnW0GQR1XS
KP-4 cell NFTVVmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXJTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xO{BvVQ>? MoGzV2FPT0WU
GAMG cell NGDQeohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLac|E2UW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42OSCwTR?= M1vOVnNCVkeHUh?=
HOS cell MnfGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml;WTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWzJI5O M{PxdnNCVkeHUh?=
CHL-1 cell NXHYb2UyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHyyOlZKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= M{fSO3NCVkeHUh?=
AGS cell NGDoV5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XofmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj64OkBvVQ>? NXTqepdDW0GQR1XS
MDA-MB-157 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXMVZo{UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj65NkBvVQ>? MVrTRW5ITVJ?
HSC-3 cell M4jx[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFnPZVlKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= MXzTRW5ITVJ?
CAL-72 cell MlnDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXLZSm9sUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytO|Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB{IH7N M1rXb3NCVkeHUh?=
NBsusSR cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjRTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?= MWfTRW5ITVJ?
ES7 cell MnXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUmgcm0> M1jmeHNCVkeHUh?=
H-EMC-SS cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?= MX\TRW5ITVJ?
NCI-H1703 cell NIK1dHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jVOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> NFXGbGpUSU6JRWK=
BHT-101 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLQZmVKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N Ml7iV2FPT0WU
SK-OV-3 cell NYLacY5IT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3qUY1{UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> NIfWbZRUSU6JRWK=
EW-24 cell NV;CV5FRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjjXnZkUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2= M3;QZ3NCVkeHUh?=
PSN1 cell NU[0PVA5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2\UUGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFQhdk1? MXzTRW5ITVJ?
OVCAR-8 cell M13JZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWfmZos{UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=> NYHESWNuW0GQR1XS
NCI-H1563 cell NWnIemVMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDXOZdzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkGzJI5O NWH4V4VVW0GQR1XS
SW756 cell NHTKd4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? NWHCO|UzW0GQR1XS
A375 cell NX;E[HNyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\OWHFKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P NUD4W|BQW0GQR1XS
Ca9-22 cell M3Pm[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\WbWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zPSCwTR?= MmDZV2FPT0WU
SW1990 cell NY\1cXhsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|Ihdk1? NEPLSYFUSU6JRWK=
ES4 cell M{n5SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwM{mgcm0> M3y2NnNCVkeHUh?=
HCE-T cell M3jI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? NGSweW9USU6JRWK=
MOLT-16 cell NVP2d3RNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmXWTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE42OyCwTR?= M2D1UnNCVkeHUh?=
HSC-4 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfXcJRTUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?= NG\6fo5USU6JRWK=
NCI-SNU-1 cell M2Tne2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX65T2xiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O MUTTRW5ITVJ?
EW-11 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrtRnMzUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQSCwTR?= M{CycXNCVkeHUh?=
HT-1080 cell M2PIcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37hPGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2= NVz0V|I6W0GQR1XS
MES-SA/Dx5 cells M1;pXWN6fG:2b4jpZ4l1gSCjc4PhfS=> NHrzZ5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> MljSNlM6Ozd7OEG=
SW1710 cell M4Xacmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHHd|BUUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF4IH7N MWrTRW5ITVJ?
EW-1 cell NFf3SZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O MXfTRW5ITVJ?
BV-173 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFjT[o9KdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= M1qwbnNCVkeHUh?=
TE-8 cell NWLJe|ByT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjJNnJKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQyKG6P MnzMV2FPT0WU
G-401 cell M{DYdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPkb3I5UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= NVHRb5VFW0GQR1XS
KOSC-2 cell NEXmWWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXq2bWh6UW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N Mm\nV2FPT0WU
HuCCT1 cell M3TUe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlLKTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P NHzt[WZUSU6JRWK=
FADU cell NFLuN|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPW[ZFKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P MkLaV2FPT0WU
MHH-ES-1 cell Mmq1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnrCTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2= M1rt[3NCVkeHUh?=
ES3 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHj3[41KdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? NUfHSmhDW0GQR1XS
OVCAR-4 cell M{\4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P M{LQRnNCVkeHUh?=
HD-MY-Z cell M{TuPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{iyWGlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTFibl2= NInmPJhUSU6JRWK=
human JAR cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4jBSmlvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65O{BvVQ>? NEPXcWtUSU6JRWK=
A427 cell NYfzT|hlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O MXnTRW5ITVJ?
697 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHhTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O NEjtXZpUSU6JRWK=
OVCAR-3 cell MmCzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1? NUO0UHlQW0GQR1XS
human NB14 cell M1;zb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFL6TYhKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P MXrTRW5ITVJ?
GB-1 cell NGjsS3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWOw[XN7UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?= M3\iR3NCVkeHUh?=
COR-L105 cell NYfTPI03T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml;oTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2= NX3z[ZFPW0GQR1XS
647-V cell NWHFc|NMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj65JI5O MoXZV2FPT0WU
human K5 cell M1\mXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXHkfIREUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUegcm0> Mo\iV2FPT0WU
DMS-273 cell NYXHPHM6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnSSYFZUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> MWXTRW5ITVJ?
UM-UC-3 cell MlnGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUm5ZYFkUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> NIHmN|ZUSU6JRWK=
HEL cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> M1vPPXNCVkeHUh?=
human KU-19-19 cell M2HibWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjqT5Q5UW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> NGOw[VFUSU6JRWK=
MC-IXC cell MmW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPDU3JDUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjF5IH7N MnO1V2FPT0WU
human H4 cell Mk\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIi1dFlKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6yOUBvVQ>? MlvQV2FPT0WU
NUGC-3 cell NWflOpVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuN|Mhdk1? NIr2bJFUSU6JRWK=
CHP-212 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVX0cIJXUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> M1TJO3NCVkeHUh?=
human SW982 cell M1TjZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3vFNmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P NIS1OZJUSU6JRWK=
C-33-A cell NX;Ob3Z4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mof0TY5pcWKrdHnvckBw\iCqdX3hckBENTN|LVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlU5KG6P Mm\uV2FPT0WU
PC-3 cell NH3qWlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTDRnF{UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= NWrTT3BlW0GQR1XS
COLO-684 cell MmjkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlvpTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= M{jTN3NCVkeHUh?=
SNU-387 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHSzRodKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N NV3hUJhUW0GQR1XS
U251 cell M4H2S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnuyTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OkBvVQ>? NVPzWW5QW0GQR1XS
A673 cell MoW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfKTY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuOkBvVQ>? NHH4cYhUSU6JRWK=
human T47D cell NIq0emVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? NFjlVFBUSU6JRWK=
A549 cell NXPN[Wh2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O NWX0PIFTW0GQR1XS
PC-14 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mke4TY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlc{KG6P NGLPc5lUSU6JRWK=
A704 cell M4XrcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXTMRnNyUW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPDVibl2= MVLTRW5ITVJ?
MCF7 cell NEHjPVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|MT6zOkBvVQ>? NI\IS2NUSU6JRWK=
PC3 cells NFuzV|JHfW6ldHnvckBie3OjeR?= M2LSOWlvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0> MX[yNVM1OTZ5NR?=
F-36P cells Mk\UVJJwdGmoZYLheIlwdiCjc4PhfS=> NWPwNZcySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?= M4Hie|IyOzRzNke1
OCI-AML2 cells MXfQdo9tcW[ncnH0bY9vKGG|c3H5 NUDsW|JJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPR2kuSU2OMjDj[YxteyxiSVO1NF0xNjN3IN88US=> NIq2XGozOTN2MU[3OS=>
K562 cells NXzpVo5LWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNuIFnDOVA:OThizszN NX;KUlZqOjF|NEG2O|U>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID